Kineta Company Description
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States.
The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers.
It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. formerly known as Yumanity Therapeutics, Inc. and changed its name to Kineta, Inc., in December 2016.
The company was incorporated in 2006 and is headquartered in Mercer Island, Washington. As of June 30, 2025, Kineta, Inc. operates as a subsidiary of TuHURA Biosciences, Inc.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
Contact Details
Address: 7683 SE27th Street Mercer Island, Delaware 98040 United States | |
| Phone | 206 378 0400 |
Stock Details
| Ticker Symbol | KANT |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig W. Philips | President and Secretary |
| Keith A. Baker | Chief Financial Officer and Treasurer |
| Dr. Thierry Guillaudeux Ph.D. | Chief Scientific Officer |
| Gary Gentges | Executive Vice President of Corporate Development |